Quipt Home Medical Eyes $260M Private Buyout at a 54% Premium

CINCINNATI, OH – February 04, 2026 – Quipt Home Medical Corp. (NASDAQ: QIPT; TSX: QIPT) is on the verge of a significant transformation, moving from a publicly traded entity to a privately held company. The U.S.-based respiratory care provider has entered into a definitive agreement to be acquired by affiliates of private equity firm Kingswood Capital Management, L.P., and investment firm Forager Capital Management, LLC, in an all-cash deal valued at approximately US$260 million, including the assumption of existing debt.

Shareholders are being offered US$3.65 per share, a figure that has captured the market's attention. The company has now formally filed and begun mailing its definitive proxy statement, setting the stage for a crucial special shareholder meeting on March 3, 2026, where the fate of the transaction will be decided.

A Premium Offer After Persistent Pursuit

The US$3.65 per share offer represents a substantial premium for Quipt’s investors. It is a 54% premium over the company's 30-day volume-weighted average price as of December 12, 2025, the last trading day before the deal was announced. More strikingly, it marks a 162% premium to the stock’s price on May 19, 2025, the day before Forager Capital publicly disclosed a previous, unsolicited proposal to acquire the company.

This agreement is the culmination of a lengthy engagement by Forager, a significant shareholder that has been advocating for a sale to maximize value. The Alabama-based firm made a non-binding offer of US$3.90 per share in January 2025, which Quipt’s board declined at the time as undervaluing the company. Forager later went public with a US$3.10 per share proposal in May 2025, signaling its persistent interest. The final negotiated price of US$3.65 appears to be a middle ground that has won the unanimous approval of Quipt’s Board of Directors.

This recommendation is backed by a strong show of insider confidence. The company’s directors and executive officers, who collectively own approximately 11.3% of the outstanding shares, have entered into voting support agreements to vote in favor of the acquisition. Forager Fund, LP, which holds about 9.5%, has also committed its shares, bringing the total locked-in vote to approximately 20.8% of all issued and outstanding shares.

A New Strategy Fueled by Private Capital

Upon completion of the deal, Quipt will be delisted from the NASDAQ and Toronto Stock Exchange, transitioning into a new phase of growth under private ownership. The acquiring partners have been clear about their intentions to leverage Quipt's established platform for further expansion.

In a joint statement, Kingswood Partner Michael Niegsch and Forager Partner Johnny Wilhelm praised Quipt's "high quality, scaled respiratory care platform defined by its patient-centric care model, durable referral relationships, and attractive recurring revenue base." Their vision involves partnering with Quipt’s leadership to "reignite the M&A engine to expand in strategic markets, while continuing to invest in people, technology, and best-in-class clinical care."

This strategy suggests a shift away from the quarterly pressures of public markets toward a long-term, aggressive growth plan. Kingswood, a Los Angeles-based firm with roughly $3.2 billion in assets under management, brings significant capital and experience in middle-market investments. The plan to reignite M&A is particularly notable given the fragmented nature of the home medical equipment sector and Quipt's own history as an active consolidator.

Quipt has steadily grown its footprint through strategic acquisitions, including a majority stake in Michigan-based Hart Medical Equipment for approximately $60 million in September 2025. In its 2025 fiscal year, the company grew its customer base by 10% to serve 346,000 unique patients. While it posted a net loss for the year, its gross margin remained strong at 72.21%, and analysts projected sales to increase over 24% in 2026 to more than $305 million. The private equity backing is expected to provide the resources to accelerate this M&A strategy without the immediate need for public financing.

Consolidation Heats Up in Home Healthcare

The acquisition of Quipt is a clear indicator of the powerful consolidation trend sweeping through the U.S. home healthcare and Durable Medical Equipment (DME) market. This sector, characterized by a mix of large players and smaller, independent providers, is seen as ripe for investment. The growing demand for in-home care, driven by an aging population and a preference for treatment outside of hospital settings, makes companies like Quipt attractive targets.

Private equity firms are drawn to the industry's recurring revenue streams—from equipment rentals and supply refills—and the potential for creating efficiencies through scale. By acquiring and integrating regional players, firms can expand their geographic reach, negotiate better terms with suppliers and payors, and streamline back-office operations.

However, the industry also faces significant headwinds, including complex regulatory oversight, potential changes to reimbursement rates from Medicare and private insurers, supply chain vulnerabilities, and persistent labor shortages. Operating as a larger, well-capitalized private entity could provide Quipt with greater resilience to navigate these challenges while executing its growth plans.

The Path to Closing: Shareholder Vote Looms

With the proxy materials now in the hands of shareholders, the focus shifts to the special meeting on March 3, 2026. For the arrangement to proceed, it must be approved by a special resolution requiring at least two-thirds of the votes cast by all shareholders. A second, simple majority vote is also required, which excludes the votes of any "interested parties" as defined by Canadian securities regulations, ensuring protection for minority shareholders.

The company has already cleared several key hurdles. The Supreme Court of British Columbia issued an interim order on January 23, 2026, authorizing the meeting and the voting process. Furthermore, the waiting period under the U.S. Hart-Scott-Rodino (HSR) Antitrust Improvements Act has expired, removing a significant regulatory obstacle.

Quipt has retained Carson Proxy Advisors to assist shareholders with questions and voting procedures ahead of the proxy voting deadline of 10:00 a.m. (Eastern Standard Time) on February 27, 2026. Assuming shareholder and final court approvals are secured, the transaction is expected to close in the first half of 2026, marking the end of Quipt's tenure as a public company and the beginning of its next chapter under new ownership.